Compare Cassava Sciences Inc (FLNA) vs Fortinet Inc (FTNT) Price & Performance

FLNA trades at $0.8168 with minimal daily movement (+0.13%). The stock shows bearish technical signals with negative moving averages but has beaten earnings expectations for three consecutive quarters. Recent FDA approval to lift the clinical hold on simufilam enables Phase 2a epilepsy trials, providing potential catalyst. However, the company reports zero revenue, negative EBITDA of -$95.19M, and concerning cash flow trends with net cash outflow of -$33.07M in 2025.

While analyst consensus is strongly bullish (67% buy ratings), fundamental weaknesses including negative profitability metrics and cash burn present significant risks. The FDA approval provides near-term optimism for the epilepsy drug pipeline, but execution risk remains high given the company's financial position and lack of current revenue streams.

Fortinet (FTNT) trades at $194.75, up 2.89% today and near its 52-week high of $203. The stock shows strong bullish momentum with consistent earnings beats (Q1-Q2 2026) and robust revenue growth from $4.4B in 2022 to $6.8B in 2025. Technical indicators signal bullish moving averages but overbought RSI levels. The company maintains exceptional profitability with 80.2% gross margins and 28.17% net income margins, though valuation multiples remain elevated with P/E at 66.82.

Outlook remains positive driven by cybersecurity demand and AI security tailwinds, with 2026 revenue guidance of $7.5B. Key risks include high valuation sensitivity and competitive pressures. Analyst consensus is mixed (42% Buy, 49% Hold) with $158.64 price target below current levels, suggesting cautious optimism amid strong fundamentals.